Jump to ContentJump to Main Navigation

Drug Metabolism and Drug Interactions

Drug Metabolism and Drug Interactions is the official journal of the European Society of Pharmacogenomics and Theranostics

Editor-in-Chief: Siest, Gérard

Editorial Board Member: Chen, Bing / Dahl, Marja-Liisa / Devinsky, Ferdinand / Henney, Adriano / Hirata, Rosario D. C. / Hubacek, Jaroslav A. / Ingelman-Sundberg, Magnus / Llerena, Adrián / Maitland-van de Zee, Anke-Hilse / Manolopoulos, Vangelis G. / Marc, Janja / Melichar, Bohuslav / Meyer, Urs A. / Sadee, Wolfgang / Simmaco, Maurizio / Turpeinen, Miia / Schaik, Ron / Visvikis-Siest, Sophie / Zanger, Ulrich M.

4 Issues per year

VolumeIssuePage

Issues

In silico pharmacology for a multidisciplinary drug discovery process

Santiago Schiaffino Ortega1 / Luisa Carlota López Cara1 / 1

1Departamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Universidad de Granada, Granada, España

Corresponding author: María Kimatrai Salvador, Departamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Universidad de Granada, Campus de Cartuja s/n Granada, 18071, España

Citation Information: Drug Metabolism and Drug Interactions. Volume 27, Issue 4, Pages 199–207, ISSN (Online) 2191-0162, ISSN (Print) 0792-5077, DOI: 10.1515/dmdi-2012-0021, November 2012

Publication History:
Received:
2012-06-07
Accepted:
2012-10-05
Published Online:
2012-11-09

Abstract

The process of bringing new and innovative drugs, from conception and synthesis through to approval on the market can take the pharmaceutical industry 8–15 years and cost approximately $1.8 billion. Two key technologies are improving the hit-to-drug timeline: high-throughput screening (HTS) and rational drug design. In the latter case, starting from some known ligand-based or target-based information, a lead structure will be rationally designed to be tested in vitro or in vivo. Computational methods are part of many drug discovery programs, including the assessment of ADME (absorption-distribution-metabolism-excretion) and toxicity (ADMET) properties of compounds at the early stages of discovery/development with impressive results. The aim of this paper is to review, in a simple way, some of the most popular strategies used by modelers and some successful applications on computational chemistry to raise awareness of its importance and potential for an actual multidisciplinary drug discovery process.

Keywords: docking; in silico pharmacology; pharmacophore; rational drug design; structure-activity relationship (SAR)

Comments (0)

Please log in or register to comment.
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.